Non-dosimetric risk factors for radiation-induced lung toxicity

Feng-Ming (Spring) Kong and **Shulian Wang**

Department of Radiation Oncology, GRU Cancer Center and Medical College of Georgia, 821 St. Sebastian Way, HK112F | Augusta, GA 30912, Office: 706-721-2979, Fax: 706-721-7248

Feng-Ming (Spring) Kong: fkong@gru.edu

Abstract

The decision to administer a radical course of radiotherapy is largely influenced by the dose-volume metrics of the treatment plan, but what are the patient related and other factors that may independently increase the risk of radiation lung toxicity? Poor pulmonary function has been regarded as a risk factor and relative contraindication for patients having radical radiotherapy, but recent evidence suggests that patients with poor spirometry may tolerate conventional or high dose radiotherapy as well as, if not better than, patients with normal function. However, caution may need to be exercised in patients with underlying interstitial pulmonary fibrosis. Further there is emerging evidence of molecular markers of increased risk of toxicity. This review will discuss patient related and risk factors other than dosimetry for radiation lung toxicity.

Radiotherapy (RT) is a mainstay local treatment for non-small cell lung cancer. Radiation-induced lung toxicity (RILT) is one of the most common dose-limiting toxicities from thoracic irradiation, especially for lung cancer patients who require a high radiation dose and frequently have reduced lung function caused by tumor or pre-existing lung diseases. RILT includes radiation pneumonitis (RP) and pulmonary fibrosis. RP develops in the first few weeks or months after radiotherapy with symptoms of cough, shortness of breath, chest pain, and low grade fever. It can be reversible but in severe cases may be life-threatening. Pulmonary fibrosis can develop even years after radiotherapy sometimes as a sequential effect of acute injury, leading to permanent impairment of lung function. RP has been more widely investigated than pulmonary fibrosis because it develops earlier and is thus more conveniently evaluated.

The risk of RILT for each individual patient remains unclear. In general, it is related to clinical patient factors, inherited biologic factor, tumor factors, dosimetric parameters, and other interventions. Dosimetric parameters such as mean lung dose (MLD) have been consistently found to be related to RILT and have been well documented [1, 2]. Patient-related factors have also been investigated and identifying those who have an increased risk of RILT to tailor RT would make the treatment safer and more beneficial. In this review, we

will discuss the most relevant risk factors other than dosimetry for RILT in patients with lung cancer, including patient age, gender, smoking status, pre-existing lung disease, pulmonary function, previous treatment, tumor location, genetic phenotypes and inflammatory cytokines, in order to better select patients for RT or prescribe radiation dose based on personalized toxicity estimate.

Age

Older patients are believed to have poorer tolerance to RT and are often given less aggressive treatment. Indeed, some studies [3–7] and a pooled analysis of 13 studies before 2012 [8] showed older age significantly increased the risk of RILT, but others did not find an association between age and the risk of RILT [9–13]. A study including 369 patients found age (70 years) was an independent predictor for both grade 2 (OR = 1.99) and grade 3 RP (OR = 8.90) [4]. Severe RP (grade 4) was also more common in elderly patients, occurring in 1% of those <70 years, compared with 6% of elderly patients [7]. Another study found age (68 years) increased the risk of grade 3 RP and combining age with dosimetric factors and pulmonary fibrosis score improved the predictability of severe RP [6]. However, in a study of 576 patients by Jin et al, there was no difference in the incidence of grade 3 RP between patients 60 years and >60 years [10]. It was not clear whether there was a difference between patients and >70 years. In all, age should be considered as a risk factor for RILT, but a clear cut-off value may not exist due to the heterogeneity among the older patients. A comprehensive evaluation of other risk factors such as co-morbidities, performance status, frailty and pulmonary function should be done before making a determination on RT.

Gender

The effect of gender on RILT is not clear. Women often have smaller lung volumes than men and they are prone to have autoimmune diseases that may predispose to a greater risk of lung injury. It has been shown that the absolute lung volume spared from 5 Gy (sV5) was significantly associated with the risk of RILT; the smaller the sV5, the higher the risk of RP [14]. The sV5 would be smaller for women than men given similar radiation field sizes. But women also have, on average, smaller tumor volumes [15]. On the other hand, women are often non-smokers and thus have better lung reserve. One study showed that gender was independently associated with grade 3 RP, 15% for women and 4% for men [11]. In another study, when using decision trees in the model, gender was selected as an input variable in which female has higher risk of grade 2 RP [16]. However, in the majority of studies [12–14, 17, 18] and a meta-analysis [8], no association of gender with RP risk was seen. Therefore, gender should not be given too much consideration when prescribing RT.

Smoking status

The association between smoking and RILT is controversial. Smoking has been found to have a protective effect on the risk of RILT in several studies [10, 12, 19] and in a pooled analysis (OR=0.65) [8]. Ongoing tobacco use [12], or current smokers [20], or recent quitters [19] had less risk of RP than others. Jin et al found in 575 patients that smoking status was the only clinical factor that affected the risk of grade 3 RP independent of

dosimetric factors. Patients who had never smoked (''non-smokers'') had the highest incidence RP (37%), whereas patients who reported being smokers at the time of diagnostic workup (''smokers'') had the lowest incidence (14%) [10]. Indeed, smoking damaged lung i.e. "dead lung" may not be as sensitive to radiation injury as healthy, well perfused lung, as it is mostly fibrotic or non-functional airspace. Tobacco-induced immunosuppression could be another possible explanation for this effect [21, 22]. But these findings should in no way be taken to encourage patient smoking, because smoking is a risk factors for poorer survival [23, 24]. In fact, smokers often have limited pulmonary reserve, and are at a greater risk to develop respiratory failure even after a modest reduction of lung function.

Pre-existing lung disease

There are two types of pre-existing lung disease that might influence the risk of RILT: interstitial lung disease (ILD) and chronic obstructive pulmonary disease (COPD) which includes pulmonary emphysema. Clinically, acute exacerbation of preexisting lung disease following radiotherapy can confound the definitive diagnosis of RP [25]. Patients with pre-existing ILD appear to be more susceptible to acute lung injury after RT, resulting in acute ILD exacerbation. It has been reported that for patients with pre-existing interstitial changes on computed tomography (CT), the incidence of RP ≥ grade 3 was significantly increased to 26% as compared to 3% for those with normal lung [26]. In another study, grade 4–5 RP occurred in 57% of patients with interstitial pneumonitis (IP) as compared to 2% of those without [27]. Ueki et al recently reported that pre-existing ILD was a significant risk factor for symptomatic and severe RP in patients with NSCLC treated with stereotactic body radiotherapy (SBRT). The incidence of ≥ G2 RP (55.0% versus 13.3%) and ≥ G3 RP (10.0% versus 1.5%) were significantly higher in patients with ILD (+) than ILD (−) [28]. Yamaguchi et al reported that subclinical ILD was not a predictor of Grade ≥ 2 RP in patients treated with thoracic SBRT, but the rate of extensive RP beyond the irradiated field was significantly higher in the patients with subclinical ILD [29]. Therefore, caution must be taken when considering RT for patients with ILD, particularly IP. Safe dosimetric dose limits of standard practice may not be safe for this population.

There are no consistent results regarding the predictive role of COPD on RILT. Some studies showed that the presence of COPD significantly increased the risk of RILT [30, 31], whereas others did not [10, 14, 29, 32]. In Kimura's study, using CT classification of pulmonary emphysema, the incidence of RP increased significantly as the emphysema grade increased. In patients with emphysema grades 0, 1, 2 and 3 or greater, the incidence of RP was 16.5%, 9.1%, 8.6% and 54.0% [31]. Using pulmonary function (FEV 1 and FVC) to grade COPD, Takeda et al found severe COPD did not increase the risk of grade ≥ 2 RP in lung cancer patients treated with SBRT. Patients with COPD tended to have milder RP than those with normal lungs [32]. At least two factors need to be considered for the impact of COPD on a patient's risk for RILT. On one side, emphysematous lung is often filled with trapped air, contains less lung parenchyma to radiation exposure. On the other side, patients with COPD can also have borderline lung function so that they have limited tolerance to any reduction in lung function. In all, contrary to patients with ILD, patients with emphysema might tolerate RT better than what has been traditionally believed. COPD is not a

contraindication to definitive RT. The tolerance of patients with COPD may be associated with the functional level of the lung.

Pulmonary function

Adequate pulmonary function (PF) is required for cancer treatment such as thoracic surgery to decrease the risk of pulmonary complications and patients with very poor PF are generally considered unfit for surgery. Traditionally, PF was also used to select patients for RT. PF parameters such as percent predicted value of forced expiratory volume at the 1st second (FEV1), forced vital capacity (FVC) and diffusion capacity of lung for carbon monoxide (DLCO), have been used as the primary indicators of whole lung function. Earlier RTOG studies limited patients with FEV1 of greater than 0.85, later to 0.75 liters for radiation therapy protocol participation. However, there is no consistent evidence to support the association between PF parameters and RILT. A few studies reported impaired baseline PF predicted higher risk of symptomatic RILT, in which lower baseline levels of absolute FEV1[11, 33], or FEV1% [34], DLCO % [35], or PaO2 [36] were significantly associated with the risk of RILT. Other studies have not shown significant correlations between PF and RILT [10, 12, 37–40]. Interestingly, one recent study with 260 patients showed that lower FEV1 may associate with reduced risk of RILT; patients with symptomatic RILT had marginally higher FEV1 than those without (71.7% vs. 65.9% of predicted), $p = 0.077$) [18]. It is of course possible that the patients included in the studies had already been selected by physicians and typically those who had very poor PF were not offered definitive RT. The jury is still out whether poor lung function is associated with high or lower risk of RILT.

The physiological changes in PF as a result of RT for lung cancer patients are quite complex. Tumor shrinkage after RT could alleviate bronchial obstruction or compression, thus improve lung ventilation. As noted above, impaired lung may be less susceptible to radiation damage compared with normal lung that has better cellular oxygenation. An early prospective study showed that patients with better (> 50%) baseline FEV1 tended to lose significant lung function after RT, while most of those with poor FEV1 prior to RT underwent only a mild decrease or even an improvement in PF [41]. A recent study reported more reduction in diffusing capacity than ventilation after RT [42]. DLCO fell in the majority of patients after RT, and pre-RT DLCO   50% was associated with greater post-RT declines in DLCO, whereas the FEV1 per unit of vital capacity (FEV1/VC) showed an increase and decrease after RT in a similar percentage of patients.

The global lung function is a result of a combination of regional function of different functioning parts of the lung. Based on regional function level, cause of dysfunction, and potentially recoverability, the whole lung can be divided into the following different regions: normal functioning lung, temporarily dysfunctional lung caused by tumor, and unrecoverable nonfunctioning or low-functioning lung caused by pre-existing lung disease. Through regional function mapping by ventilation (V) or perfusion (Q) single-photon emission computed tomography (SPECT), we can understand more about the radiosensitivity of the different functioning lungs. A study from our group (Yuan et al) indicated that the normal functioning lung is most susceptible to RT damage and about 20% of patients had worsened function in this region after RT; unrecoverable nonfunctioning or

low-functioning lungs only experienced worsened regional function in 3.6% and 9.3% of patients, they cannot be injured more because they are already or nearly "dead"; 55% of temporarily dysfunctional lung caused by tumor can partially or completely recover to normal function levels [43]. This finding indicated that lung is not a uniform organ; instead it has regional differences in function, and lung cancer patients experience heterogeneous changes to RT in different functioning regions. Regional function mapping, especially accessing combined regional V/Q function [44] or optimizing the treatment plan accordingly [45] might be more helpful in guiding RT.

Tumor factors and tumor location

Tumor location may influence the risk of RILT based on the findings in several studies, indicating patients with tumors in the lower lobes had higher risk of RP [13, 46–48], though some inconsistent findings exist [49]. Bradley et al reported a significantly greater risk for patients with tumors located in the inferior part of the lung [13]. A study by Seppenwoolde et al also found that irradiation of caudally located lung tumors resulted in a greater risk of RP than irradiation of tumors located in other parts of the lungs, and the incidence of RP was 11% and 40% for cranial and caudal tumors [46], respectively. Similarly, another study showed when the lower lung was included in the radiation site, the incidence of pneumonitis was 70% compared with 20% for other lobes [47]. The mean lung dose of the lower portion instead of the upper portion of the lungs was significantly correlated with grade $\geq$ 3 RP [50]. A pooled meta-analysis confirmed that mid or inferior lung tumors are associated with increased risk of RP compared with upper lung locations [8]. Increased RP risk with lower tumor locations possibly reflect radiosensitivity differences among different lung regions, due to a greater density of target cells in the lower lung [51] or strong out-of-field effect of lower lung irradiation [52]. The other explanations may be more physiologically pronounced perfusion and ventilation of the lower lung (better oxygenation) or increased tumor motion during RT causing more normal lung to be irradiated to a low dose. Therefore, caution should be taken when lower lung is included in the RT field.

Tumor volume and tumor stage

Tumor volume and tumor stage themselves may not be important in predicting the risk of RILT. Some studies showed primary gross tumor volume had a trend of negative association with $\geq$ G2 RP ($p = 0.09$) [37], as T2 tumors had a higher rate of G2 RP than T1 in patients treated with SBRT (17.9% vs 4.4%, p=0.02) [53], but other studies showed field size ($\geq$ 200cm2 vs. < 200cm^2) [47], or tumor volume (cut off at median) was not associated with $\geq$ G2 RP [54]. There are some data suggesting that stage I/II disease predicted lower risk of RILT than stage III [20] or stage III/IV [55], however the majority found tumor stage was not associated with the risk of $\geq$ G2 RP [5, 18, 33, 56, 57], or $\geq$ G3 RP [4, 10, 11, 14, 36, 58–61]. It is understandable that, the effect of tumor volume and stage may be confounded by other risk factors, and also depends on the lung dosimetry which is related to an individual's lung volume [54]: larger or more advanced tumors do not necessarily result in poorer lung dosimetry.

Previous radiation

For patients who develop recurrent or secondary lung tumors after previous thoracic RT, re-irradiation is often the only treatment option. Under such a circumstance, RT associated risk of serious RILT should be considered. The literature is limited on this topic. One study showed 1/19 patients developed grade 3 RP and a survival benefit was found for those who had longer intervals between initial RT and re-irradiation (>12 month) and good performance status (ECOG PS scores of 0–2) [62]. Other studies showed grade 1–2 RP in 22% of patients and no grade 3 or greater RP in 23 patients [63] or grade 2–3 RP in 19/34 of patients [64]. Recently, Liu et al analyzed 72 patients treated with stereotactic ablative radiation therapy (SABR) after previous thoracic RT and found 20.8% of patients developed grade 3 RP. ECOG PS scores of 2–3 before SABR, FEV1 65% before SABR, V20 30% of the composite plan, and an initial PTV in the bilateral mediastinum were significantly associated with increased risk of RP [65]. Therefore, previous thoracic RT is not a contraindication for RT when recurrent or secondary lung tumors occurred. However, patient selection criteria should be strict, requiring consideration of other risk factors such as PS, pulmonary function, complete lung dosimetry including V20 of the composite plan and initial radiation area for lung safety. For such cases, lung functional mapping using V/Q SPECT is recommended to avoid further damage of the functioning lung [44, 45].

Previous chemotherapy

There are conflicting results on the influence of previous chemotherapy on the risk of RILT. For an individual patient with bulky tumor, induction chemotherapy may shrink the tumor, thus decrease the radiation field and the volume of normal lung and the risk of RILT. A dosimetric analysis of 25 patients with NSCLC showed that approximately 30% of patients had at least a 20% reduction in tumor volume after induction chemotherapy, which translated into a small statistically significant reduction (5%) in the predicted risk of RP [66]. However, a retrospective analysis of 223 patients by Wang et al did not show a significant association in the risk of grade 3 RP between patients with and without induction chemotherapy [14]. In contrast, in a model using decision tree analysis, another study demonstrate that chemotherapy before RT was a risk factor for grade 2 RP [16]. Some patients may also progress during induction chemotherapy. Induction mitomycin C was found to increase the risk of RP: Grade 2 radiation pneumonitis was 31.2% among patients who received induction mitomycin C and 10.6% among those who did not [30]. In summary, the use of induction chemotherapy should be on an individual basis and there is no consistent evidence regarding its use and the risk of RILT.

Treatment Factors

The most important treatment factor is radiation lung dosimetry, which is not the focus of this review. In brief, MLD and V20 are the most frequently reported and the most reproducible lung dosimetric factors. It is recommended to limit V20 to 30–35 %, and MLD to 20–23 Gy (with conventional fractionation), if one wants to limit the risk of RP to 20% in NSCLC patients treated with definitive RT [67]. One must note that each dosimetric parameter is highly correlated with one another [37]. There is an unanswered

question of what is associated with higher risk of RILT: "a little (dose) to a lot (lung), versus "a lot (dose) to a little (lung)". Tucker et al found that given the same MLD, high doses to small lung volumes ("a lot to a little") were worse than low doses to large volumes ("a little to a lot") [68]. In addition, functional dosimetric parameters may provide better predictive outcome than physical dosimetric factors, which were reported in very limited studies with small size of patients [33] [69, 70].

The other important treatment factor is concurrent chemotherapy with radiotherapy (CCRT), which is the standard of care in patients with a locally advanced NSCLC or limited stage SCLC. CCRT is often considered to be a risk factor for RILT, as it is a more aggressive form of treatment. Indeed, patients treated in early RTOG trials showed CCRT significantly increased grade 3 late lung toxicity as compared with sequential chemotherapy and RT (20% vs. 10%) [71]. Agents associated with known risk to escalate RILT such as bleomycin and gemcitabine are not used in concurrent practice any more. A meta-analysis by Palma et al based on individual patient data suggested the choice of concurrent chemotherapy regimen played an important role in RP risk, particularly in the elderly. The risk of grade 2 RP for patients treated with combination of concomitant carboplatin and paclitaxel with RT was 3.3 fold that of cisplatin and etoposide with RT. Patients >65 years receiving concurrent carboplatin-paclitaxel regimens had the highest risk of RP [72]. In another study with 369 patients analyzed, a higher rate of grade 3 RP was also found for concurrent docetaxel/cisplatin schedule (18.4%) than that for concurrent vinorelbine/cisplatin schedule (9.5%) [4]. However, a weekly carboplatin-paclitaxel regimen remains in common use in practice and RTOG trials, such as RTOG0617 and RTOG1107. The RP rate was acceptable from preliminary report of RTOG0617. Nevertheless, concurrent taxane chemotherapy regimens may increase the risk of RP, and should be chosen carefully, maybe with stricter dose constraints of the lung.

Biologic factors/Genetic phenotypes

Individual genetic phenotypes determine the intrinsic radiosensitivity of lung to radiation. The pathogenesis of RILT may involve direct radiation cytotoxicity to normal lung tissue, secondary inflammatory changes and fibrotic remodeling [73]. Thus genetic variation in key genes in DNA repair, inflammation and oxidative stress pathways may ameliorate or exacerbate the effects of a given radiation dose to the lungs. In recent years, the candidate gene single-nucleotide polymorphism (SNP) approach has been used in several studies to evaluate the intrinsic radiosensitivity of lung to radiation. SNPs in a series of genes associated primarily with radiation-related processes were genotyped in lung cancer patients (Caucasian or Han Chinese) who developed RILT (Table 1).

Two studies provided independent replication cohorts for validation. Pang et al [55] showed lung cancer patients who had the CC genotype heat-shock protein B1 (as opposed to CG or GG) had a higher probability of severe RP after RT in both the training and validation datasets. Pu et al [74] further evaluated the functional correlation of SNPS with radiosensitivity. In his study, a total of 11,930 SNPs from 904 inflammation-related genes were included in the discovery analysis. Of these, 1,321 were significantly associated with RP. Nine SNPs were significantly associated with RP in the validation population. These

SNPs were also selected to assess for functional correlation with radiation sensitivity via the lymphoblastoid cell line model system that incorporates baseline host gene expression and cytotoxicity following RT. Forty five SNPs in three genes (*PRKCE*, *DDX58*, and *TNFSF7*) were found to be significantly associated with radiation response, which are more than 5.8 that would be expected by chance alone. *DDX58* Rs11795343 was consistently significantly associated with increased risk of developing RP.

The risk of RP increased as the number of unfavorable genotypes increased. In Hildebrandt's study [19], 12 common polymorphisms were found to be significantly associated with risk of RP. Compared to patients with 0 to 2 risk genotypes, the risk of RP was 13.3-fold and 69.4-fold for those carrying three and four or more unfavorable genotypes. In Yang's study [75], compared with the absence of unfavorable genotype, the risk of RP increased with presence of P53 72Arg/Arg genotype (HR,2.24) or ATM–111A allele (AA or GA genotype) (HR, 2.36). The presence of both risk genotypes, i.e., the P53 72Arg/Arg and the ATM –111AA or GA genotypes, had a significantly greater risk of RP (HR, 6.17).

Incorporation of genetic patient information in the form of SNPs from a relatively small set of genes can markedly improve the ability of the LKB MLD model to predict RP risk. In Tucker's study, with 5 SNPs in the TGFβ, TNFα, VEGF, XRCC1, and APEX1 genes, it was possible to distinguish cohorts with >50% risk versus <10% risk of RP when exposed to high MLDs [76]. Vinogradskiy et al. found a model-generated personalized lung-dose limit from dosimetric constraints and SNPs could result in a clinically significant change to the prescription, which would help to determine how much dose can be safely delivered to the tumor and normal tissues on individual basis [77].

Future studies using a genome wide association studies (GWAS) approach with sufficient numbers of patients to investigate SNPs associated with RILT may find more accurate RILT-related genotypes than the target gene approach. However, in addition to genetic make-up, epigenetics and other proteins also play a role in determining the individual risk of RILT. For example, our group identified serum micro RNA expression (Bi et al presented, but unpublished data), and plasma levels of proteins (Cai et al) such as C4b-binding protein alpha chain, complement C3, and vitronectin as predicting risk factors for RILT using a proteomic approach [78, 79], and these biomarkers play important roles in the inflammatory response.

Biologic factors/Cytokines

Inflammatory cytokines released by cells trigger inflammation and respond to infections, and their levels have been inconsistently shown to serve as early surrogate markers for RILT. Blood inflammatory cytokines such as transforming growth factor beta-1 (TGF-β1), interleukin 8 (IL-8), Krebs von den Lungen-6 (KL-6) have been reported to predict RILT in some studies.

While it is likely that no single molecule or cytokine will provide adequate predictive power in all cases, TGF-β1, a prototype of multifunctional regulators of cell growth and differentiation, a proinflammatory and profibrotic cytokine, has been singled out to play a

pivotal role in promoting lung damage via various pathways. TGF-β1, normally present in a latent form, can be activated by ionizing radiation-induced free radicals. Activated TGF-β1 directly stimulates connective tissue formation and decreases collagen degradation, and plays an important role in both the inhibition of epithelial cell proliferation and in the development of tissue fibrosis and radiation induced inflammation. Increased local TGF-β1 expression is accompanied by an elevated plasma concentration. The predictive value of TGF-β1 for human RILT was first reported by Anscher et al. (1993) in individuals with advanced breast cancer treated by high-dose chemotherapy and autologous bone marrow transplantation [82]. Further studies including those from our group demonstrated that changes in plasma TGF-β1 levels may identify individuals at high risk for the development of RILT [83–86]. A persistently elevated plasma TGF-β1 above baseline level at the end of radiotherapy [83, 87], or the ratio of TGF-β1 level over baseline during radiotherapy [88] or a significant elevation of TGF-β1 level at 4 weeks after RT [89] were all significantly associated with symptomatic RILT. A return of the plasma TGF-β1 to normal could identify patients who would not develop RP [83]. An earlier study from Fu et al. also reported that the combination of end/pre-RT TGF-β1 level and lung V30 could stratify patients into low, intermediate and high risk groups, and patients with both high end/pre-RT TGF-β1 level and V30 30% had the highest risk of SRILT as 43% [87]. Further study from that group using grade 1 RP as an endpoint found TGF-β1 was not predictive for RILT except for the group of patients with a high V30. Among patients with lung V30 > 30%, those with higher end/pre-RT TGF-β1 ratio had a significantly higher incidence of RILT [90]. Others reported that TGF-β1 levels in the bronchial alveolar lavage fluid were also predictive of RILT [91].

One must note that the role of TGF-β1 on RILT can be confounded by tumors, as circulating TGF-β1 levels may be produced by lung tumors. The dynamics of the plasma TGF-β1 could be a marker of RILT as well as a marker of tumor response to treatment [92]. Elevation of plasma TGF-β1 levels in lung cancer patients may also contribute to individual inabilities to normally process TGF-β1 [93]. These individuals have often lost the mannose 6-phosphate/insulin-like growth factor 2 receptor, a key factor associated with TGF-β1 activation. As TGF-β1 is richly stored in platelets, careful sample handling is important to avoid artificially elevated plasma TGF-β1 level from platelet contamination/degradation [93, 94]. Some studies reported that plasma TGF-β1 was not significantly associated with the risk of RILT [95, 96]; some of these studies applied sample handling procedures that were not controlled for platelet contamination (Table 2). Nevertheless, a meta-analysis including 7 studies showed end/pre-RT TGF-β1 ratio 1 was a risk factor for RP [1]. Plasma TGF-β1 level, particularly the radiation induced elevation, would possibly allow for identifying patients at high risk for RILT.

A complex cytokine network is involved in the process of RILT. A comprehensive illustration of cytokine cascade is beyond the scope of this review, but a few studies reporting the potential for combining multiple cytokines in predicting the risk of RILT are noted. Plasma inflammatory cytokine profiling assays were performed in 55 patients analyzing the levels of 17 cytokines before radiotherapy, but the study failed to identify a specific signature to predict the risk of RILT, and only lower baseline levels of IL-8 were associated with an increased risk of developing symptomatic RILT [97]. A model combining pretreatment levels of multiple circulating cytokines and MLD may more accurately predict

RILT. Our group (Stenmark et.al.) reported that combining IL-8, TGF-β1, and MLD into a single model yielded an improved predictive ability compared to either variable alone [98]. Combination of cytokines and other parameters could also serve as a pre-screening tool for patients before RT. By prescreening patients for serum KL-6 and surfactant protein-D (SP-D) as biomarkers and considering ILD on CT scans, appropriate patients were selected for SBRT. As a result, the frequency of grade 4–5 RP in a Japanese study has shown a decrease, from 18.8% before 2005 to 3.5% after 2006 [27]. Because these parameters can be obtained during the early course of RT or at baseline, this model has the potential to serve as a predictive tool to prescribe personalized RT.

Summary

Older patients, pre-existing interstitial lung disease, tumor located in lower lung, concurrent taxane chemotherapy, several SNPs phenotypes, radiation induced elevation in TGF-β1 and lower levels of IL-8 have been shown to increase the risk of RILT, in addition to the standard parameters of lung dosimetry. However, a consistent predictive model for the risk of RILT is not available. There is potential in investigating the intrinsic sensitivity of individual patients by focusing on genetic and epigenetic characteristics, and combining them with clinical and dosimetric factors in a model, but large numbers of patients and validations are needed.

References

1. Zhang XJ, Sun JG, Sun J, Ming H, Wang XX, Wu L, Chen ZT. Prediction of radiation pneumonitis in lung cancer patients: a systematic review. J Cancer Res Clin Oncol. 2012; 138(12):2103–2116. [PubMed: 22842662]

2. Rodrigues G, Lock M, D'Souza D, Yu E, Van Dyk J. Prediction of radiation pneumonitis by dose - volume histogram parameters in lung cancer--a systematic review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2004; 71(2):127–138. [PubMed: 15110445]

3. Leprieur EG, Fernandez D, Chatellier G, Klotz S, Giraud P, Durdux C. Acute radiation pneumonitis after conformational radiotherapy for nonsmall cell lung cancer: clinical, dosimetric, and associated-treatment risk factors. J Cancer Res Ther. 2013; 9(3):447–451. [PubMed: 24125981]

4. Dang J, Li G, Zang S, Zhang S, Yao L. Risk and predictors for early radiation pneumonitis in patients with stage III non-small cell lung cancer treated with concurrent or sequential chemoradiotherapy. Radiat Oncol. 2014; 9:172. [PubMed: 25074618]

5. Claude L, Perol D, Ginestet C, Falchero L, Arpin D, Vincent M, Martel I, Hominal S, Cordier JF, Carrie C. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2004; 71(2):175–181. [PubMed: 15110451]

6. Tsujino K, Hashimoto T, Shimada T, Yoden E, Fujii O, Ota Y, Satouchi M, Negoro S, Adachi S, Soejima T. Combined analysis of V20, VS5, pulmonary fibrosis score on baseline computed tomography, and patient age improves prediction of severe radiation pneumonitis after concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014; 9(7):983–990.

7. Schild SE, Stella PJ, Geyer SM, Bonner JA, McGinnis WL, Mailliard JA, Brindle J, Jatoi A, Jett JR. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol. 2003; 21(17):3201–3206. [PubMed: 12874270]

8. Vogelius IR, Bentzen SM. A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis. Acta Oncol. 2012; 51(8):975–983. [PubMed: 22950387]

9. Wen J, Liu H, Wang Q, Liu Z, Li Y, Xiong H, Xu T, Li P, Wang LE, Gomez DR, et al. Genetic variants of the LIN28B gene predict severe radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy. Eur J Cancer. 2014; 50(10):1706–1716. [PubMed: 24780874]

10. Jin H, Tucker SL, Liu HH, Wei X, Yom SS, Wang S, Komaki R, Chen Y, Martel MK, Mohan R, et al. Dose-volume thresholds and smoking status for the risk of treatment-related pneumonitis in inoperable non-small cell lung cancer treated with definitive radiotherapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2009; 91(3): 427–432. [PubMed: 18937989]

11. Robnett TJ, Machtay M, Vines EF, McKenna MG, Algazy KM, McKenna WG. Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. International journal of radiation oncology, biology, physics. 2000; 48(1):89–94.

12. Hernando ML, Marks LB, Bentel GC, Zhou SM, Hollis D, Das SK, Fan M, Munley MT, Shafman TD, Anscher MS, et al. Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. International journal of radiation oncology, biology, physics. 2001; 51(3):650–659.

13. Bradley JD, Hope A, El Naqa I, Apte A, Lindsay PE, Bosch W, Matthews J, Sause W, Graham MV, Deasy JO. A nomogram to predict radiation pneumonitis, derived from a combined analysis of RTOG 9311 and institutional data. International journal of radiation oncology, biology, physics. 2007; 69(4):985–992.

14. Wang S, Liao Z, Wei X, Liu HH, Tucker SL, Hu CS, Mohan R, Cox JD, Komaki R. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). International journal of radiation oncology, biology, physics. 2006; 66(5):1399–1407.

15. Ball DL, Fisher RJ, Burmeister BH, Poulsen MG, Graham PH, Penniment MG, Vinod SK, Krawitz HE, Joseph DJ, Wheeler GC, et al. The complex relationship between lung tumor volume and survival in patients with non-small cell lung cancer treated by definitive radiotherapy: a prospective, observational prognostic factor study of the Trans-Tasman Radiation Oncology Group (TROG 99.05). Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2013; 106(3):305–311. [PubMed: 23333017]

16. Das SK, Zhou S, Zhang J, Yin FF, Dewhirst MW, Marks LB. Predicting lung radiotherapy-induced pneumonitis using a model combining parametric Lyman probit with nonparametric decision trees. International journal of radiation oncology, biology, physics. 2007; 68(4):1212–1221.

17. Hope AJ, Lindsay PE, El Naqa I, Alaly JR, Vicic M, Bradley JD, Deasy JO. Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parameters. International journal of radiation oncology, biology, physics. 2006; 65(1):112–124.

18. Wang J, Cao J, Yuan S, Ji W, Arenberg D, Dai J, Stanton P, Tatro D, Ten Haken RK, Wang L, et al. Poor baseline pulmonary function may not increase the risk of radiation-induced lung toxicity. International journal of radiation oncology, biology, physics. 2013; 85(3):798–804.

19. Hildebrandt MA, Komaki R, Liao Z, Gu J, Chang JY, Ye Y, Lu C, Stewart DJ, Minna JD, Roth JA, et al. Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. PLoS One. 2010; 5(8):e12402. [PubMed: 20811626]

20. Yin M, Liao Z, Liu Z, Wang LE, Gomez D, Komaki R, Wei Q. Functional polymorphisms of base excision repair genes XRCC1 and APEX1 predict risk of radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy. International journal of radiation oncology, biology, physics. 2011; 81(3):e67–e73.

21. Miller LG, Goldstein G, Murphy M, Ginns LC. Reversible alterations in immunoregulatory T cells in smoking. Analysis by monoclonal antibodies and flow cytometry. Chest. 1982; 82(5):526–529. [PubMed: 6982152]

22. Bjermer L, Hallgren R, Nilsson K, Franzen L, Sandstrom T, Sarnstrand B, Henriksson R. Radiation-induced increase in hyaluronan and fibronectin in bronchoalveolar lavage fluid from

breast cancer patients is suppressed by smoking. Eur Respir J. 1992; 5(7):785–790. [PubMed: 1499701]

23. Janjigian YY, McDonnell K, Kris MG, Shen R, Sima CS, Bach PB, Rizvi NA, Riely GJ. Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer. Cancer. 2010; 116(3):670–675. [PubMed: 20029977]

24. Shiono S, Katahira M, Abiko M, Sato T. Smoking is a perioperative risk factor and prognostic factor for lung cancer surgery. Gen Thorac Cardiovasc Surg. 2014

25. Kocak Z, Evans ES, Zhou SM, Miller KL, Folz RJ, Shafman TD, Marks LB. Challenges in defining radiation pneumonitis in patients with lung cancer. International journal of radiation oncology, biology, physics. 2005; 62(3):635–638.

26. Sanuki N, Ono A, Komatsu E, Kamei N, Akamine S, Yamazaki T, Mizunoe S, Maeda T. Association of computed tomography-detected pulmonary interstitial changes with severe radiation pneumonitis for patients treated with thoracic radiotherapy. J Radiat Res. 2012; 53(1): 110–116. [PubMed: 22302051]

27. Yamashita H, Kobayashi-Shibata S, Terahara A, Okuma K, Haga A, Wakui R, Ohtomo K, Nakagawa K. Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy. Radiat Oncol. 2010; 5:32. [PubMed: 20459699]

28. Ueki N, Matsuo Y, Togashi Y, Kubo T, Shibuya K, Iizuka Y, Mizowaki T, Togashi K, Mishima M, Hiraoka M. Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival after Stereotactic Body Radiation Therapy for Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014

29. Yamaguchi S, Ohguri T, Ide S, Aoki T, Imada H, Yahara K, Narisada H, Korogi Y. Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis. Lung Cancer. 2013; 82(2):260–265. [PubMed: 24054547]

30. Rancati T, Ceresoli GL, Gagliardi G, Schipani S, Cattaneo GM. Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2003; 67(3):275–283. [PubMed: 12865175]

31. Kimura T, Togami T, Takashima H, Nishiyama Y, Ohkawa M, Nagata Y. Radiation pneumonitis in patients with lung and mediastinal tumours: a retrospective study of risk factors focused on pulmonary emphysema. Br J Radiol. 2012; 85(1010):135–141. [PubMed: 21385918]

32. Takeda A, Kunieda E, Ohashi T, Aoki Y, Oku Y, Enomoto T, Nomura K, Sugiura M. Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy. Chest. 2012; 141(4):858–866. [PubMed: 21885726]

33. Wang D, Zhu J, Sun J, Li B, Wang Z, Wei L, Yin Y, Sun H, Fu Z, Zhang X, et al. Functional and biologic metrics for predicting radiation pneumonitis in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy. Clin Transl Oncol. 2012; 14(12):943–952. [PubMed: 22855174]

34. Dehing-Oberije C, De Ruysscher D, van Baardwijk A, Yu S, Rao B, Lambin P. The importance of patient characteristics for the prediction of radiation-induced lung toxicity. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2009; 91(3): 421–426. [PubMed: 19147245]

35. Chen S, Zhou S, Zhang J, Yin FF, Marks LB, Das SK. A neural network model to predict lung radiation-induced pneumonitis. Med Phys. 2007; 34(9):3420–3427. [PubMed: 17926943]

36. Inoue A, Kunitoh H, Sekine I, Sumi M, Tokuuye K, Saijo N. Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis. International journal of radiation oncology, biology, physics. 2001; 49(3):649–655.

37. Kong FM, Hayman JA, Griffith KA, Kalemkerian GP, Arenberg D, Lyons S, Turrisi A, Lichter A, Fraass B, Eisbruch A, et al. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. International journal of radiation oncology, biology, physics. 2006; 65(4):1075–1086.

38. Fay M, Tan A, Fisher R, Mac Manus M, Wirth A, Ball D. Dose-volume histogram analysis as predictor of radiation pneumonitis in primary lung cancer patients treated with radiotherapy. International journal of radiation oncology, biology, physics. 2005; 61(5):1355–1363.

39. Marks LB, Munley MT, Bentel GC, Zhou SM, Hollis D, Scarfone C, Sibley GS, Kong FM, Jirtle R, Jaszczak R, et al. Physical and biological predictors of changes in whole-lung function following thoracic irradiation. International journal of radiation oncology, biology, physics. 1997; 39(3):563–570.

40. Tsujino K, Hirota S, Endo M, Obayashi K, Kotani Y, Satouchi M, Kado T, Takada Y. Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. International journal of radiation oncology, biology, physics. 2003; 55(1):110–115.

41. Choi NC, Kanarek DJ. Toxicity of thoracic radiotherapy on pulmonary function in lung cancer. Lung Cancer. 1994; 10(Suppl 1):S219–S230. [PubMed: 8087514]

42. Lopez Guerra JL, Gomez DR, Zhuang Y, Levy LB, Eapen G, Liu H, Mohan R, Komaki R, Cox JD, Liao Z. Changes in pulmonary function after three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, or proton beam therapy for non-small-cell lung cancer. International journal of radiation oncology, biology, physics. 2012; 83(4):e537–e543.

43. Yuan ST, Frey KA, Gross MD, Hayman JA, Arenberg D, Cai XW, Ramnath N, Hassan K, Moran J, Eisbruch A, et al. Changes in global function and regional ventilation and perfusion on SPECT during the course of radiotherapy in patients with non-small-cell lung cancer. International journal of radiation oncology, biology, physics. 2012; 82(4):e631–e638.

44. Yuan ST, Frey KA, Gross MD, Hayman JA, Arenberg D, Curtis JL, Cai XW, Ramnath N, Kalemkerian GP, Ten Haken RK, et al. Semiquantification and classification of local pulmonary function by V/Q single photon emission computed tomography in patients with non-small cell lung cancer: potential indication for radiotherapy planning. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011; 6(1):71–78.

45. Meng X, Frey K, Matuszak M, Paul S, Ten Haken R, Yu J, Kong FM. Changes in functional lung regions during the course of radiation therapy and their potential impact on lung dosimetry for non-small cell lung cancer. International journal of radiation oncology, biology, physics. 2014; 89(1):145–151.

46. Seppenwoolde Y, De Jaeger K, Boersma LJ, Belderbos JS, Lebesque JV. Regional differences in lung radiosensitivity after radiotherapy for non-small-cell lung cancer. International journal of radiation oncology, biology, physics. 2004; 60(3):748–758.

47. Yamada M, Kudoh S, Hirata K, Nakajima T, Yoshikawa J. Risk factors of pneumonitis following chemoradiotherapy for lung cancer. Eur J Cancer. 1998; 34(1):71–75. [PubMed: 9624240]

48. Nakamura T, Fuwa N, Kodaira T, Tachibana H, Tomoda T, Nakahara R, Inokuchi H. Clinical outcome of stage III non-small-cell lung cancer patients after definitive radiotherapy. Lung. 2008; 186(2):91–96. [PubMed: 18097718]

49. Vinogradskiy Y, Tucker SL, Liao Z, Martel MK. Investigation of the relationship between gross tumor volume location and pneumonitis rates using a large clinical database of non-small-cell lung cancer patients. International journal of radiation oncology, biology, physics. 2012; 82(5):1650–1658.

50. Yorke ED, Jackson A, Rosenzweig KE, Merrick SA, Gabrys D, Venkatraman ES, Burman CM, Leibel SA, Ling CC. Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy. International journal of radiation oncology, biology, physics. 2002; 54(2):329–339.

51. Tucker SL, Liao ZX, Travis EL. Estimation of the spatial distribution of target cells for radiation pneumonitis in mouse lung. International journal of radiation oncology, biology, physics. 1997; 38(5):1055–1066.

52. Moiseenko VV, Battista JJ, Hill RP, Travis EL, Van Dyk J. In-field and out-of-field effects in partial volume lung irradiation in rodents: possible correlation between early dna damage and functional endpoints. International journal of radiation oncology, biology, physics. 2000; 48(5):1539–1548.

53. Allibhai Z, Taremi M, Bezjak A, Brade A, Hope AJ, Sun A, Cho BC. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small

cell lung cancer. International journal of radiation oncology, biology, physics. 2013; 87(5):1064–1070.

54. Wang W, Xu Y, Schipper M, Matuszak MM, Ritter T, Cao Y, Ten Haken RK, Kong FM. Effect of normal lung definition on lung dosimetry and lung toxicity prediction in radiation therapy treatment planning. International journal of radiation oncology, biology, physics. 2013; 86(5):956–963.

55. Pang Q, Wei Q, Xu T, Yuan X, Lopez Guerra JL, Levy LB, Liu Z, Gomez DR, Zhuang Y, Wang LE, et al. Functional promoter variant rs2868371 of HSPB1 is associated with risk of radiation pneumonitis after chemoradiation for non-small cell lung cancer. International journal of radiation oncology, biology, physics. 2013; 85(5):1332–1339.

56. Mak RH, Alexander BM, Asomaning K, Heist RS, Liu CY, Su L, Zhai R, Ancukiewicz M, Napolitano B, Niemierko A, et al. A single-nucleotide polymorphism in the methylene tetrahydrofolate reductase (MTHFR) gene is associated with risk of radiation pneumonitis in lung cancer patients treated with thoracic radiation therapy. Cancer. 2012; 118(14):3654–3665. [PubMed: 22144047]

57. Zhang L, Yang M, Bi N, Fang M, Sun T, Ji W, Tan W, Zhao L, Yu D, Lin D, et al. ATM polymorphisms are associated with risk of radiation-induced pneumonitis. International journal of radiation oncology, biology, physics. 2010; 77(5):1360–1368.

58. Niu X, Li H, Chen Z, Liu Y, Kan M, Zhou D, Li Z, Ye X, Shen S, Lv C, et al. A study of ethnic differences in TGFbeta1 gene polymorphisms and effects on the risk of radiation pneumonitis in non-small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2012; 7(11):1668–1675.

59. Xiong H, Liao Z, Liu Z, Xu T, Wang Q, Liu H, Komaki R, Gomez D, Wang LE, Wei Q. ATM polymorphisms predict severe radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy. International journal of radiation oncology, biology, physics. 2013; 85(4):1066–1073.

60. Yin M, Liao Z, Liu Z, Wang LE, O'Reilly M, Gomez D, Li M, Komaki R, Wei Q. Genetic variants of the nonhomologous end joining gene LIG4 and severe radiation pneumonitis in nonsmall cell lung cancer patients treated with definitive radiotherapy. Cancer. 2012; 118(2):528–535. [PubMed: 21717429]

61. Yuan X, Liao Z, Liu Z, Wang LE, Tucker SL, Mao L, Wang XS, Martel M, Komaki R, Cox JD, et al. Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J Clin Oncol. 2009; 27(20):3370–3378. [PubMed: 19380441]

62. Tada T, Fukuda H, Matsui K, Hirashima T, Hosono M, Takada Y, Inoue Y. Non-small-cell lung cancer: reirradiation for loco-regional relapse previously treated with radiation therapy. Int J Clin Oncol. 2005; 10(4):247–250. [PubMed: 16136369]

63. Wu KL, Jiang GL, Qian H, Wang LJ, Yang HJ, Fu XL, Zhao S. Three-dimensional conformal radiotherapy for locoregionally recurrent lung carcinoma after external beam irradiation: a prospective phase I–II clinical trial. International journal of radiation oncology, biology, physics. 2003; 57(5):1345–1350.

64. Okamoto Y, Murakami M, Yoden E, Sasaki R, Okuno Y, Nakajima T, Kuroda Y. Reirradiation for locally recurrent lung cancer previously treated with radiation therapy. International journal of radiation oncology, biology, physics. 2002; 52(2):390–396.

65. Liu H, Zhang X, Vinogradskiy YY, Swisher SG, Komaki R, Chang JY. Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy. International journal of radiation oncology, biology, physics. 2012; 84(4):1017–1023.

66. Amin NP, Miften M, Thornton D, Ryan N, Kavanagh B, Gaspar LE. Effect of induction chemotherapy on estimated risk of radiation pneumonitis in bulky non-small cell lung cancer. Med Dosim. 2013; 38(3):320–326. [PubMed: 23611631]

67. Marks LB, Bentzen SM, Deasy JO, Kong FM, Bradley JD, Vogelius IS, El Naqa I, Hubbs JL, Lebesque JV, Timmerman RD, et al. Radiation dose-volume effects in the lung. International journal of radiation oncology, biology, physics. 2010; 76(3 Suppl):S70–S76.

68. Tucker SL, Mohan R, Liengsawangwong R, Martel MK, Liao Z. Predicting pneumonitis risk: a dosimetric alternative to mean lung dose. International journal of radiation oncology, biology, physics. 2013; 85(2):522–527.

69. Hoover DA, Reid RH, Wong E, Stitt L, Sabondjian E, Rodrigues GB, Jaswal JK, Yaremko BP. SPECT-based functional lung imaging for the prediction of radiation pneumonitis: a clinical and dosimetric correlation. J Med Imaging Radiat Oncol. 2014; 58(2):214–222. [PubMed: 24373453]

70. Vinogradskiy Y, Castillo R, Castillo E, Tucker SL, Liao Z, Guerrero T, Martel MK. Use of 4-dimensional computed tomography-based ventilation imaging to correlate lung dose and function with clinical outcomes. International journal of radiation oncology, biology, physics. 2013; 86(2): 366–371.

71. Byhardt RW, Scott C, Sause WT, Emami B, Komaki R, Fisher B, Lee JS, Lawton C. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. International journal of radiation oncology, biology, physics. 1998; 42(3): 469–478.

72. Palma DA, Senan S, Tsujino K, Barriger RB, Rengan R, Moreno M, Bradley JD, Kim TH, Ramella S, Marks LB, et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. International journal of radiation oncology, biology, physics. 85(2):444–450.

73. Marks LB, Yu X, Vujaskovic Z, Small W Jr, Folz R, Anscher MS. Radiation-induced lung injury. Semin Radiat Oncol. 2003; 13(3):333–345. [PubMed: 12903021]

74. Pu X, Wang L, Chang JY, Hildebrandt MA, Ye Y, Lu C, Skinner HD, Niu N, Jenkins GD, Komaki R, et al. Inflammation-related genetic variants predict toxicity following definitive radiotherapy for lung cancer. Clin Pharmacol Ther. 2014

75. Yang M, Zhang L, Bi N, Ji W, Tan W, Zhao L, Yu D, Wu C, Wang L, Lin D. Association of P53 and ATM polymorphisms with risk of radiation-induced pneumonitis in lung cancer patients treated with radiotherapy. International journal of radiation oncology, biology, physics. 2011; 79(5):1402–1407.

76. Tucker SL, Li M, Xu T, Gomez D, Yuan X, Yu J, Liu Z, Yin M, Guan X, Wang LE, et al. Incorporating single-nucleotide polymorphisms into the Lyman model to improve prediction of radiation pneumonitis. International journal of radiation oncology, biology, physics. 2013; 85(1): 251–257.

77. Vinogradskiy Y, Tucker SL, Bluett JB, Wages CA, Liao Z, Martel MK. Prescribing radiation dose to lung cancer patients based on personalized toxicity estimates. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2012; 7(11): 1676–1682.

78. Cai XW, Shedden KA, Yuan SH, Davis MA, Xu LY, Xie CY, Fu XL, Lawrence TS, Lubman DM, Kong FM. Baseline plasma proteomic analysis to identify biomarkers that predict radiation-induced lung toxicity in patients receiving radiation for non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011; 6(6):1073–1078.

79. Cai XW, Shedden K, Ao X, Davis M, Fu XL, Lawrence TS, Lubman DM, Kong FM. Plasma proteomic analysis may identify new markers for radiation-induced lung toxicity in patients with non-small-cell lung cancer. International journal of radiation oncology, biology, physics. 2010; 77(3):867–876.

80. Kelsey CR, Jackson IL, Langdon S, Owzar K, Hubbs J, Vujaskovic Z, Das S, Marks LB. Analysis of single nucleotide polymorphisms and radiation sensitivity of the lung assessed with an objective radiologic endpoin. Clin Lung Cancer. 2013; 14(3):267–274. [PubMed: 23313170]

81. Yin M, Liao Z, Yuan X, Guan X, O'Reilly MS, Welsh J, Wang LE, Wei Q. Polymorphisms of the vascular endothelial growth factor gene and severe radiation pneumonitis in non-small cell lung cancer patients treated with definitive radiotherapy. Cancer Sci. 2012; 103(5):945–950. [PubMed: 22320189]

82. Anscher MS, Peters WP, Reisenbichler H, Petros WP, Jirtle RL. Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med. 1993; 328(22):1592–1598. [PubMed: 8487801]

83. Anscher MS, Kong FM, Andrews K, Clough R, Marks LB, Bentel G, Jirtle RL. Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis. International journal of radiation oncology, biology, physics. 1998; 41(5):1029–1035.

84. Anscher MS, Kong FM, Jirtle RL. The relevance of transforming growth factor beta 1 in pulmonary injury after radiation therapy. Lung Cancer. 1998; 19(2):109–120. [PubMed: 9567247]

85. Anscher MS, Kong FM, Marks LB, Bentel GC, Jirtle RL. Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis. International journal of radiation oncology, biology, physics. 1997; 37(2):253–258.

86. Anscher MS, Marks LB, Shafman TD, Clough R, Huang H, Tisch A, Munley M, Herndon JE 2nd, Garst J, Crawford J, et al. Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation. J Clin Oncol. 2001; 19(17):3758–3765. [PubMed: 11533099]

87. Fu XL, Huang H, Bentel G, Clough R, Jirtle RL, Kong FM, Marks LB, Anscher MS. Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V(30) and transforming growth factor beta. International journal of radiation oncology, biology, physics. 2001; 50(4):899–908.

88. Zhao L, Sheldon K, Chen M, Yin MS, Hayman JA, Kalemkerian GP, Arenberg D, Lyons SE, Curtis JL, Davis M, et al. The predictive role of plasma TGF-beta1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer. Lung Cancer. 2008; 59(2):232–239. [PubMed: 17905467]

89. Kim JY, Kim YS, Kim YK, Park HJ, Kim SJ, Kang JH, Wang YP, Jang HS, Lee SN, Yoon SC. The TGF-beta1 dynamics during radiation therapy and its correlation to symptomatic radiation pneumonitis in lung cancer patients. Radiat Oncol. 2009; 4:59. [PubMed: 19943923]

90. Evans ES, Kocak Z, Zhou SM, Kahn DA, Huang H, Hollis DR, Light KL, Anscher MS, Marks LB. Does transforming growth factor-beta1 predict for radiation-induced pneumonitis in patients treated for lung cancer? Cytokine. 2006; 35(3–4):186–192. [PubMed: 16979900]

91. Barthelemy-Brichant N, Bosquee L, Cataldo D, Corhay JL, Gustin M, Seidel L, Thiry A, Ghaye B, Nizet M, Albert A, et al. Increased IL-6 and TGF-beta1 concentrations in bronchoalveolar lavage fluid associated with thoracic radiotherapy. International journal of radiation oncology, biology, physics. 2004; 58(3):758–767.

92. Kong FM, Washington MK, Jirtle RL, Anscher MS. Plasma transforming growth factor-beta 1 reflects disease status in patients with lung cancer after radiotherapy: a possible tumor marker. Lung Cancer. 1996; 16(1):47–59. [PubMed: 9017584]

93. Kong FM, Anscher MS, Sporn TA, Washington MK, Clough R, Barcellos-Hoff MH, Jirtle RL. Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor (M6P/IGF2R) locus predisposes patients to radiation-induced lung injury. International journal of radiation oncology, biology, physics. 2001; 49(1):35–41.

94. Zhao L, Wang L, Ji W, Lei M, Yang W, Kong FM. The influence of the blood handling process on the measurement of circulating TGF-beta1. European cytokine network. 2012; 23(1):1–6. [PubMed: 22456089]

95. De Jaeger K, Seppenwoolde Y, Kampinga HH, Boersma LJ, Belderbos JS, Lebesque JV. Significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer. International journal of radiation oncology, biology, physics. 2004; 58(5):1378–1387.

96. Novakova-Jiresova A, Van Gameren MM, Coppes RP, Kampinga HH, Groen HJ. Transforming growth factor-beta plasma dynamics and post-irradiation lung injury in lung cancer patients. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2004; 71(2):183–189. [PubMed: 15110452]

97. Hart JP, Broadwater G, Rabbani Z, Moeller BJ, Clough R, Huang D, Sempowski GA, Dewhirst M, Pizzo SV, Vujaskovic Z, et al. Cytokine profiling for prediction of symptomatic radiation-induced lung injury. International journal of radiation oncology, biology, physics. 2005; 63(5):1448–1454.

98. Stenmark MH, Cai XW, Shedden K, Hayman JA, Yuan S, Ritter T, Ten Haken RK, Lawrence TS, Kong FM. Combining physical and biologic parameters to predict radiation-induced lung toxicity in patients with non-small-cell lung cancer treated with definitive radiation therapy. International journal of radiation oncology, biology, physics. 2012; 84(2):e217–e222.

99. Zhao L, Wang L, Ji W, Wang X, Zhu X, Hayman JA, Kalemkerian GP, Yang W, Brenner D, Lawrence TS, et al. Elevation of plasma TGF-beta1 during radiation therapy predicts radiation-induced lung toxicity in patients with non-small-cell lung cancer: a combined analysis from Beijing and Michigan. International journal of radiation oncology, biology, physics. 2009; 74(5): 1385–1390.

Table 1

Studies Evaluating SNPs and Radiation-Induced Lung Toxicity

Study	Patients No.	Endpoint	Gene associated with lung toxicity	Gene function
Pu 2014[74]	421	G2 RP	CDC2 (rs10711) and (rs1871445) DDX58(rs11795343) and (rs7865082) FGF5(rs3733336) ETS2(rs2298560) LIMS1(rs12469016) GHR(rs4292454) TFEB(rs13202921)	Inflammation
Wen 2014[9]	362	G3 RP	LIN28B(rs314280) LIN28B (rs314276)	RNA binding protein
Pang 2013[55]	271	G3 RP	HSPB1 rs2868371	oxidative stress pathways
Xiong 2013[59]	362	G3 RP	ATM(rs189037 and rs228590)	DNA repair
Kelsey 2013[80]	39	Radiologic change	XRCC1(rs25487) BRCA1(rs16942)	DNA repair
Mark 2012[56]	136	G2(G3) RP	MTHFR (rs1801131)	oxidative stress pathways
Yin 2012[60]	195	G3 RP	LIG4(rs1805388)	DNA repair (NHEJ)
Yin 2012[81]	193	G3 RP	VEGF(rs2010963 and rs3025039)	angiogenesis
Niu 2012	46	G3 RP	TGFβ1 (rs11466345)	Inflammation
Yin 2011[20]	261	G2 RP	APEX1 D148E GG XRCC1 Q399R AA	DNA repair (BER)
Yang 2011[75]	253	G2 RP	P53 Arg72Pro	cell-cycle regulation, apoptosis and DNA repair
Hildebrandt 2010[19]	173	G2 RP	IL1A(rs1800587/ rs17561) IL8(rs4073) TNF(rs1799724) TNFRSF1B(rs1061622) MIF(rs7555622) IL4(rs2243250) IL4R(rs2070874) IL13(rs10800925) IL13(rs20541) NFKBIA(rs1799983) NOS3(rs1799983)	Inflammation
Zhang 2010[57]	253	G2 RP	ATM(rs189037) and (rs373759)	DNA repair
Yuan 2009[61]	164	G2(G3) RP	TGFβ1(rs1982073)	Inflammation

BER: Base excision repair

NHEJ: Non-homologous end joining

Table 2

Studies evaluating the association of plasma cytokines with radiation-induced lung toxicity

Author year	Patients No.	Endpoint	Cytokines (p value)	Sample handling process
Stenmark 2012[98]	58	G2 RP or symptomatic pulmonary fibrosis	IL-8 preRT and at weeks 2 and 4 during RT (p<0.01); TGF-β1 ratios at 2 and 4 weeks during RT/baseline (p=0.41, 0.26).	platelet-poor plasma[*]
Zhao 2009[99]	165	G2 RILT	TGF-β1 ratio at 4-5 weeks during RT/baseline (p < 0.001).	platelet-poor plasma[¶]
Kim 2009[89]	34	G2 RP	Change of TGF-β1 level during RT (p=0.0001)	platelet-poor plasma[§]
Zhao 2008[88]	26	G2 RILT	TGF-β1 ratio at 4 weeks during RT/baseline (p=0.015)	platelet-poor plasma[*]
Evans 2006[90]	121	G1 RP	TGF-β1 ratio at end-RT/baseline (p < 0.001).	platelet-poor plasma[*]
Hart 2005[97]	55	SRILT	IL-8 preRT (p < 0.005).	platelet-poor plasma[*]
Jaeger 2004[95]	68	G2 RP	TGF-β1 ratio at 4-6 weeks during RT/baseline (p=0.01 *inverse relation*)	plasma[‖]
Novakova-Jiresova 2004[96]	46	Symptomatic RP	TGF-β1 level (p>0.05)	plasma[†]
Fu 2001[87]	103	Symptomatic RILT	TGF-β1 level end-RT (p=0.007)	platelet-poor plasma[*]
Anscher 1998[83]	73	Symptomatic RP	TGF-β1 level end-RT (p<0.05)	platelet-poor plasma[*]

[*¶§]These studies used procedures of plasma preparation to minimize the platelet contamination or degradation, by using enough gravities, controlling time and temperature of blood setting before centrifuge, avoiding platelet contamination by using top layer of plasma.

[‖ and †]: Plasma samples may have been contaminated by platelets, as they used 1200 or 1000g which was not enough to remove the platelets in plasma supernatant.